KR100228264B1 - The synthetic method of crystalline cefuroxime axetil - Google Patents

The synthetic method of crystalline cefuroxime axetil Download PDF

Info

Publication number
KR100228264B1
KR100228264B1 KR1019970037143A KR19970037143A KR100228264B1 KR 100228264 B1 KR100228264 B1 KR 100228264B1 KR 1019970037143 A KR1019970037143 A KR 1019970037143A KR 19970037143 A KR19970037143 A KR 19970037143A KR 100228264 B1 KR100228264 B1 KR 100228264B1
Authority
KR
South Korea
Prior art keywords
cefuroxime
water
axetyl
crystalline
ethyl acetate
Prior art date
Application number
KR1019970037143A
Other languages
Korean (ko)
Other versions
KR19990015200A (en
Inventor
홍유화
신양철
구자혁
Original Assignee
김선진
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김선진, 주식회사유한양행 filed Critical 김선진
Priority to KR1019970037143A priority Critical patent/KR100228264B1/en
Publication of KR19990015200A publication Critical patent/KR19990015200A/en
Application granted granted Critical
Publication of KR100228264B1 publication Critical patent/KR100228264B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/02Preparation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

본 발명은 나트륨 세푸록심(sodium cefuroxime)과 브롬화(RS)-1-아세톡시에틸을 반응시켜 제조한 세푸록심 악세틸에 물과 에틸아세테이트(ethyl acetate) 혼합용액을 가하거나 물을 먼저 가하고 에틸아세테이트를 가하여 교반한 다음, 물로 세척하여 결정형 세푸록심 악세틸을 분리건조하는 것을 특징으로 하는 결정형 세푸록심 악세틸(Cefuroxime axetile)의 제조방법에 관한 것이다.In the present invention, a mixture of water and ethyl acetate is added to cefuroxime acetyl prepared by reacting sodium cefuroxime with bromide (RS) -1-acetoxyethyl, or water is first added to ethyl acetate. The present invention relates to a method for preparing crystalline cefuroxime axetyl (Cefuroxime axetile), characterized in that the mixture is stirred and then washed with water to separate and dry crystalline cefuroxime axetyl.

Description

결정형 세푸록심 악세틸의 제조방법Manufacturing Method of Crystalline Sepuroxime Axetyl

제1도는 본 발명에 따라 제조한 결정형 세푸록심 악세틸의 IR 스펙트럼을 나타낸 것이고,1 shows the IR spectrum of crystalline cefuroxime axetyl prepared according to the present invention,

제2도는 본 발명에 따라 제조한 결정형 세푸록심 악세틸의 X-선 스펙트럼을 나타낸 것이다.2 shows the X-ray spectrum of crystalline cefuroxime axetyl prepared according to the present invention.

본 발명은 결정형 세푸록심 악세틸(crystalline cefuroxime axetile)의 제조방법에 관한 것으로, 더욱 상세하게는 나트륨 세푸록심(sodium cefuroxime)과 브롬화(RS)-1-아세톡시에틸을 반응시켜 제조한 세푸록심 악세틸에 물과 에틸아세테이트(ethyl acetate) 혼합용액을 가하거나 물을 먼저 가하고 에틸아세테이트를 가하여 교반한 다음, 물로 세척하여 결정형 세푸록심 악세틸을 분리건조하는 것을 특징으로하는 결정형 세푸록심 악세틸(crystalline cefuroxime axetile)의 제조방법에 관한 것이다.The present invention relates to a method for preparing crystalline cefuroxime axetile, and more particularly, to cefuroxime acex produced by reacting sodium cefuroxime with brominated (RS) -1-acetoxyethyl. Water is mixed with ethyl acetate (ethyl acetate), or water is added first, followed by stirring with ethyl acetate, followed by washing with water to separate and dry crystalline cefuroxime acetyl. cefuroxime axetile).

세푸록심 악세틸(Cefuroxime axetile)은 그람양성 및 그람음성 미생물에 대하여 광범위한 활성스펙트럼을 갖는 경구용 세파계 항생제이다. 또한 세푸록심 악세틸은 그 치환기내에 부재탄소를 함유한 혼합물로서 R 및 S형의 이성체비가 약 1:1인 무정형 세푸록심 악세틸이 더욱 우수한 효과를 갖는 것으로 보고되고 있어, R 및 S형의 이성체비가 약 1:1인 무정형 세푸록심 악세틸이 현재 시판되고 있다.Cepuroxime axetile is an oral cephaic antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative microorganisms. In addition, cefuroxime axetyl is a mixture containing an absent carbon in its substituent, and it is reported that amorphous cefuroxime axetyl having an isomer ratio of R and S type of about 1: 1 has a better effect, and isomers of R and S type Amorphous cefuroxime axetyl with a ratio of about 1: 1 is currently available.

영국특허 제1,571.683호에서는 세푸록심 악세틸의 제조방법을 개시하고 있다. 그러나 영국특허 제1,571,683호에서 개시한 제조방법에 의해 생성된 세푸록심 악세틸은 잔류용매가 불순물로 포함되어 있어 이들의 제거를 위해 생성물을 결정형으로 제조한 다음, 이를 다시 무정형 세푸록심 악세틸로 전환함으로써 잔류용매등의 불순물이 제거된 세푸록심 악세틸을 제조하게 된다(유럽특허 제107,276호). 따라서 결정형 세푸록심 악세틸은 무정형 세푸록심 악세틸을 제조하기 위한 출발물질로 사용될 수 있다.British Patent No. 1,571.683 discloses a process for the preparation of cefuroxime axetyl. However, the cefuroxime axetyl produced by the preparation method disclosed in British Patent No. 1,571,683 contains residual solvents as impurities to prepare the product in crystalline form for removal thereof, and then converts it to amorphous cefuroxime axetyl. By doing so, cefuroxime axetyl from which impurities such as residual solvent are removed is produced (European Patent No. 107,276). Thus crystalline cefuroxime axetyl can be used as a starting material for preparing amorphous cefuroxime axetyl.

한편, 대한민국 특허공고 제 91-8377호에서는 결정형 세푸록심 악세틸의 제조방법을 개시한 바 있으며, 대한민국 특허공고 제 91-8377호에서는 종래의 일반적인 제조방법(영국특허 제1,571,683)으로 제조한 세푸록심 악세틸을 적당한 용매에 용해시켜 결정화 시킨 후 이를 분리하는 제조방법을 개시하고 있다. 상기 발명에서 적당한 용매로 개시한 용매는 ①에테르, ②탄화수소와 혼합될 수 있는 에스테르, ③탄화수소와 혼합될수 있는 할로겐화탄화수소, ④물과 혼합된 케톤, ⑤물과 혼합된 아마이드, 또는 ⑥물과 혼합될 수 있는 알코올 이다.Meanwhile, Korean Patent Publication No. 91-8377 discloses a method for preparing crystalline cepuroxime axetyl, and Korean Patent Publication No. 91-8377 discloses a cepuroxime manufactured by a conventional general manufacturing method (British Patent No. 1,571,683). Disclosed is a process for dissolving acetyl in a suitable solvent to crystallize it and then separating it. Solvents disclosed as suitable solvents in the present invention include (1) ether, (2) esters that can be mixed with hydrocarbons, (3) halogenated hydrocarbons that can be mixed with hydrocarbons, (4) ketones mixed with water, (5) amides mixed with water, or (6) mixed with water. It can be alcohol.

그러나, 상기 종래의 제조방법에서 결정화용매로서 개시한 에테르(예를 들어, 디이소프로필 에테르, 석유 에테르) 등은 인화점이 낮아 대량생산시 폭발의 위험성이 존재하여 공정상의 어려움이 있고, 또한 세푸록심 악세틸을 용해시키기 위해 과량의 용매를 사용함으로 제조단가가 높아지는 단점이 있다.However, ethers (eg, diisopropyl ether, petroleum ether) disclosed as crystallization solvents in the conventional manufacturing method have a low flash point and have a risk of explosion in mass production. There is a disadvantage in that the manufacturing cost is increased by using an excess solvent to dissolve the acetyl.

특히, 상기 종래의 제조반법으로 제조한 결정형 세푸록심 악세틸은 정전기가 심하게 발생하시 때문에 제조과정에서 반응용기에 생성물이 달라붙어 손실이 발생할 뿐 아니라, 다음 반응(예를들어 무정형으로의 제조과정) 수행시 취급이 매우 곤란한 단점이 있다.In particular, the crystalline cefuroxime axetyl produced by the conventional manufacturing method, since the static electricity is severely generated, the product is stuck to the reaction vessel in the manufacturing process, the loss occurs, the next reaction (for example, amorphous production process) There is a disadvantage that the handling is very difficult when performing.

이에 본 발명자들은 ①제조과정중 유기용매 사용을 최소한으로 줄여 폭발 위험성을 줄이고, ②출발물질을 용해시킬 필요가 없어 과량의 용매사용이 필요없을 뿐 아니라. ③생성물의 정전기 발생을 없엔 새로운 결정형 세푸록심 악세틸 제조방법을 개발하고자 연구를 거듭한 결과, 나트륨 세푸록심(sodium cefuroxime)과 브롬화(RS)-1-아세톡시에틸을 반응시켜 제조한 세푸록심 악세틸에 물과 에틸아세테이트(ethyl acetate)혼합용액을 가하거나 물을 먼저 가하고 에틸아세테이트를 가하여 교반한 다음, 물로 세척하여 결정형 세푸록심 악세틸을 분리건조하였을 때, 폭팔위험성도 없고, 출발물질의 용해도 필요없을 뿐 아니라, 정전기가 전혀 발생하지 않는다는 것을 발견하여 본 발명을 완성하게 되었다.Therefore, the inventors of the present invention reduce the risk of explosion by minimizing the use of organic solvents in the manufacturing process. ③ As a result of research to develop a new method for preparing crystalline cefuroxime acetyl without generating static electricity of the product, cefuroxime acex produced by reacting sodium cefuroxime with brominated (RS) -1-acetoxyethyl When the mixture of water and ethyl acetate is added to the ethyl, or water is added first, and then ethyl acetate is added, the mixture is stirred, and then washed with water to separate and dry the crystalline cefuroxime acetyl. Not only is it unnecessary, it has been found that no static electricity is generated, thus completing the present invention.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 나트륨 세푸록심(sodium cefuroxime)과 브롬화 (RS)-1-아세톡시에틸을 반응시켜 제조한 세푸록심 악세틸에 물과 에틸아세테이트(ethyl acetate)혼합용액을 가하거나 물을 먼저 가하고 에틸아세테이트를 가하여 교반한 다음, 물로 세척하여 결정형 세푸록심 악세틸을 분리건조하는 것을 특징으로 하는 결정형 세푸록심 악세틸(crystalline cefuroxime axetile)의 제조방법을 제공하는 것을 목적으로 한다.In the present invention, a mixture of water and ethyl acetate is added to cefuroxime acetyl prepared by reacting sodium cefuroxime with bromide (RS) -1-acetoxyethyl, or water is first added to ethyl acetate. It is an object of the present invention to provide a method for preparing crystalline cefuroxime axetile, characterized in that the mixture is stirred, and then washed with water to separate and dry crystalline cefuroxime acetil.

이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명에 따른 제조방법에서 출발물질로 사용한 세푸록심 악세틸은 영국특허 제1,571,683호에서 개시한 제조방법으로 제조될 수 있으며, 이를 따로 분리하거나 분리하지 아니하고 본 발명에 따른 제조방법의 출발물질로 사용할 수 있다. 영국특허 제1,571,683호에서 개시한 제조방법으로 제조된 세푸록심 악세틸을 따로 분리하지 않고 그대로 반응에 이용할 경우, 본 발명의 출발물질인 세푸록심 악세틸은 포움상(foam phase)으로 본 발명에 사용되게 된다. 본 발명에 따른 제조방법은 포움상의 세푸록심 악세틸 및 따로 분리된 세푸록심 악세틸 모두를 사용할 수 있다.Sepuroxime axetyl used as a starting material in the production method according to the present invention may be prepared by the production method disclosed in British Patent No. 1,571,683, and may be used as a starting material of the production method according to the present invention without separating or separating it separately. Can be. When the cefuroxime axetyl prepared by the preparation method disclosed in British Patent No. 1,571,683 is used in the reaction without being separated, the starting material of the present invention, cefuroxime axetyl, is used in the present invention as a foam phase. Will be. The preparation method according to the invention can use both cefuroxime axetyl and foamed sefuroxime axetyl on the foam separately.

본 발명에 따른 결정형 세푸록심 악세틸의 제조방법에서 특징적으로 사용된 결정화제인 물과 에틸아세테이트의 혼합용액(각각 별도로 가하는 것을 포함한다.)의 물과 에틸아세테이트의 부피비는 에틸아세테이트의 물에 대한 부피비가 5 내지 20

Figure kpo00002
인 것이 바람직하다.The volume ratio of water and ethyl acetate in the mixed solution of water and ethyl acetate, which are characteristically used in the preparation method of the crystalline cefuroxime acetyl according to the present invention (including separately added), is the ratio of ethyl acetate to water. 5 to 20 volume ratio
Figure kpo00002
Is preferably.

또한, 물과 에틸아세테이트의 혼합용액(각각 별도로 가하는 것을 포함한다.)을 세푸록심 악세틸에 가할 때 반응온도는 5 내지 35

Figure kpo00003
에서 반응시키는 것이 바람직하고, 교반시간은 5 내지 24시간이 바람직하다.In addition, the reaction temperature is 5 to 35 when a mixed solution of water and ethyl acetate (including those added separately) is added to cefuroxime acetil.
Figure kpo00003
It is preferable to make it react at, and the stirring time of 5 to 24 hours is preferable.

상기와 같은 본 발명에 따른 제조방법으로 결정형 세푸록심 악세틸을 제조할 경우 하기 실시예에서 확인할 수 있는 바와 같이 효과적으로 결정형 세푸록심 악세틸을 제조할 수 있으며, 또한 R : S의 이성체비가 약 1 : 1로 유지된 결정형 세푸록심 악세틸을 제조할 수 있다.When the crystalline cefuroxime axetyl is prepared by the preparation method according to the present invention as described above, the crystalline cefuroxime axetyl can be effectively produced as can be seen in the following examples, and the isomer ratio of R: S is about 1: 1. Crystalline cefuroxime axetyl maintained at 1 can be prepared.

특히, 본 발명에 따른 제조방법은 종래의 제조방법과는 달리 유기용매를 소량으로 사용하고 대부분의 반응을 물을 매개로 반응시킴으로써 폭발 위험성을 배제할 수 있고, 출발물질인 세푸록심 악세틸을 용해시키지 않고 곧바로 결정형 세푸록심 악세틸을 제조할 수 있기 때문에 종래의 제조방법과 같은 과량의 용매사용이 필요없는 장점이 있다. 또한, 본 발명의 제조방법은 정전기가 전혀 발생하지 않기 때문에 취급이 용이하고 건조과정중 발생하는 손실이 전혀 없는 장점이 있다.In particular, the manufacturing method according to the present invention, unlike the conventional manufacturing method, it is possible to exclude the risk of explosion by using a small amount of organic solvent and reacting most of the reaction through water, dissolving the starting material cefuroxime axetyl Since it is possible to prepare the crystalline cefuroxime axetyl immediately without the use, there is an advantage that does not require the use of excess solvent as in the conventional manufacturing method. In addition, the manufacturing method of the present invention has the advantage that it is easy to handle and no loss occurs during the drying process because no static electricity is generated at all.

이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나, 이것이 본 발명의 범위를 제한하는 것이 아니다. 세푸록심 악세틸의 R 및 S 이성체는 각각 A 및 B로 표시하였고 이성체비는 A : B로 표시하였다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, this does not limit the scope of the invention. The R and S isomers of cefuroxime axetyl are represented by A and B, respectively, and the isomer ratio is represented by A: B.

[참고예][Reference Example]

[포움상의 세푸록심 악세틸의 제조][Preparation of Sepuroxime Axetyl on Foam]

영국특허 제1,571,683호에서 개시한 제조방법으로 세푸록심 악세틸을 제조하였다. 즉, 디메틸아세트아미드 165

Figure kpo00004
에 나트륨 세푸록심 30g을 투입하고 0 내지 5
Figure kpo00005
로 냉각한 후 브롬화 (RS)-1-아세톡시에틸 18g을 가하여 동온도에서 1.5시간 교반하였다. 여기에 탄산칼륨 0.78g을 넣고 동온도에서 2시간 교반하였다. 반응액을 1N HCI 1300
Figure kpo00006
에 투입한 후 에틸아세테이트 900
Figure kpo00007
를 첨가한 후 유기층을 분리하였다. 유기층을 3
Figure kpo00008
중탄산나트륨 용액으로 세척한 후, 목탄 3g을 투입하여 30분간 교반하였다. 에틸아세테이트로 세척된 규조토 베드를 사용하여 이를 여과한 후 에틸아세테이트로 세척하여 얻은 유기층을 완전히 감압증류하여 포움상의 세푸록심 악세틸(32g)을 얻었다.Sepuroxime axetyl was prepared by the preparation method disclosed in British Patent No. 1,571,683. Dimethylacetamide 165
Figure kpo00004
30 g of sodium cefuroxime is added to 0-5
Figure kpo00005
After cooling to 18 g of brominated (RS) -1-acetoxyethyl was added and stirred at the same temperature for 1.5 hours. 0.78 g of potassium carbonate was added thereto and stirred at the same temperature for 2 hours. 1N HCI 1300
Figure kpo00006
Ethyl acetate 900
Figure kpo00007
After the addition of the organic layer was separated. Organic layer 3
Figure kpo00008
After washing with sodium bicarbonate solution, 3 g of charcoal was added and stirred for 30 minutes. The diatomaceous earth bed washed with ethyl acetate was filtered and the organic layer obtained by washing with ethyl acetate was completely distilled under reduced pressure to obtain cefuroxime acetil (32 g) on foam.

[실시예 1]Example 1

참고예에서 제조한 포움상의 세푸록심 악세틸에 에틸아세테이트 150

Figure kpo00009
와 증류수 1500
Figure kpo00010
혼합용액을 20
Figure kpo00011
에서 가하여 12시간 동안 교반한 후 이를 여과한 다음, 물 150
Figure kpo00012
로 세척한 후 건조하여 결정형 세푸록심 악세틸 30g을 수득하였다.Cefuroxime Axetyl on foam prepared in Reference Example Ethyl Acetate 150
Figure kpo00009
And distilled water 1500
Figure kpo00010
Mixed solution 20
Figure kpo00011
Stirred for 12 hours, filtered and water 150
Figure kpo00012
Washed with and dried to obtain 30 g of crystalline cefuroxime axetyl.

수율;87.4

Figure kpo00013
Yield; 87.4
Figure kpo00013

A : B ; 1.04 : 1.00A: B; 1.04: 1.00

함량; 98

Figure kpo00014
(HPLC)content; 98
Figure kpo00014
(HPLC)

[실시예 2]Example 2

에틸아세테이트 79

Figure kpo00015
를 사용한 것을 제외하고는 실시예1과 동일한 방법으로 반응시켜 결정형 세푸록심 악세틸 29.4g을 수득하였다.Ethyl Acetate 79
Figure kpo00015
Except for using, the reaction was carried out in the same manner as in Example 1, to obtain 29.4 g of crystalline cefuroxime axetyl.

수율;85.7

Figure kpo00016
Yield; 85.7
Figure kpo00016

A : B; 1.06 : 1.00A: B; 1.06: 1.00

함량 ; 97.2

Figure kpo00017
(HPLC)content ; 97.2
Figure kpo00017
(HPLC)

[실시예 3]Example 3

에틸아세테이트 118.5

Figure kpo00018
를 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켜 결정형 세푸록심 악세틸 30.2g을 수득하였다.Ethyl acetate 118.5
Figure kpo00018
Except for using, the reaction was carried out in the same manner as in Example 1, to obtain 30.2 g of crystalline cefuroxime axetyl.

수율;87.9

Figure kpo00019
Yield; 87.9
Figure kpo00019

A : B; 1.02 : 1.00A: B; 1.02: 1.00

함량; 98.2

Figure kpo00020
(HPLC)content; 98.2
Figure kpo00020
(HPLC)

[실시예 4]Example 4

에틸아세테이트 264.7

Figure kpo00021
를 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 반응시켜 결정형 세푸록심 악세틸 27g을 수득하였다.Ethyl acetate 264.7
Figure kpo00021
Reaction was carried out in the same manner as in Example 1, except that 27 g of crystalline cefuroxime axetyl was obtained.

[실시예 5]Example 5

참고예에서 제조한 세푸록심 악세틸에 에틸아세테이트 150

Figure kpo00022
와 증류수 1500
Figure kpo00023
혼합용액을 20
Figure kpo00024
에서 가하여 8시간동안 교반한 후 이를 여과한 다음, 물 150
Figure kpo00025
로 세척한 후 건조하여 결정형 세푸록심 악세틸 25g을 수득하였다.Cefuroxime Axetyl Ethyl Acetate 150 Prepared in Reference Example
Figure kpo00022
And distilled water 1500
Figure kpo00023
Mixed solution 20
Figure kpo00024
Stirred for 8 hours, filtered and water 150
Figure kpo00025
Washed with and dried to obtain 25g of crystalline cefuroxime axetyl.

수율 ; 72.8

Figure kpo00026
Yield; 72.8
Figure kpo00026

A : B ; 1.10 : 1.00A: B; 1.10: 1.00

함량; 96.8

Figure kpo00027
(HPLC)content; 96.8
Figure kpo00027
(HPLC)

[실시예 6]Example 6

참고예에서 제조한 세푸록심 악세틸에 에틸아세테이트 150

Figure kpo00028
와 증류수 1500
Figure kpo00029
혼합용액을 5에서 가하여 12시간 동안 교반한 후 이를 여과한 다음, 물 150
Figure kpo00031
로 세척한 후 건조하여 결정형 세푸록심 악세틸 29g을 수득하였다.Cefuroxime Axetyl Ethyl Acetate 150 Prepared in Reference Example
Figure kpo00028
And distilled water 1500
Figure kpo00029
Mixed solution 5 Stirred for 12 hours, filtered and water 150
Figure kpo00031
Washed with and dried to obtain 29 g of crystalline cefuroxime axetyl.

수율;84.5

Figure kpo00032
Yield: 84.5
Figure kpo00032

A : B; 1.03 : 1.00A: B; 1.03: 1.00

함량 ; 97.8

Figure kpo00033
(HPLC)content ; 97.8
Figure kpo00033
(HPLC)

[실시예 7]Example 7

참고예에서 제조한 세푸록심 악세틸에 증류수 1500

Figure kpo00034
를 20
Figure kpo00035
에서 가하여 30분간 교반 한 후 에틸아세테이트 150
Figure kpo00036
를 서서히 가하였다. 20
Figure kpo00037
에서 12시간 동안 교반한 후 이를 여과한 다음, 물 150
Figure kpo00038
로 세척한 후 건조하여 결정형 세푸록심 악세틸 30g을 수득하였다.Sepuroxime Acetyl produced in Reference Example 1500 distilled water
Figure kpo00034
20
Figure kpo00035
After stirring for 30 minutes, ethyl acetate 150
Figure kpo00036
Was added slowly. 20
Figure kpo00037
After stirring for 12 hours at filtered water, 150
Figure kpo00038
Washed with and dried to obtain 30 g of crystalline cefuroxime axetyl.

수율 ; 87.4

Figure kpo00039
Yield; 87.4
Figure kpo00039

A : B; 1.04 : 1.00A: B; 1.04: 1.00

함량; 98

Figure kpo00040
(HPLC)content; 98
Figure kpo00040
(HPLC)

[시험예 1][Test Example 1]

[결정형 확인시험(IR시험)][Crystalline Formation Test (IR Test)]

실시예 1에서 제조한 결정형 세푸록심 악세틸을 KBr방법(대한약전 6개정)으로 적외선 스텍트럼을 측정한 결과, 제1도에서 확인할 수 있는 바와 같이 결정형 세푸록심 악세틸의 특징인 스펙트럼이 1500-2000cm-1에서 보여주고 있어 결정형 세푸록심 악세틸이 효과적으로 제조된 것을 알 수 있다.As a result of measuring the infrared spectrum of the crystalline cefuroxime axetyl prepared in Example 1 by the KBr method (6 amendments to the Korean Pharmacopoeia), as shown in FIG. It is shown in cm-1 that the crystalline Sepuroxime Axetyl is effectively produced.

[시험예 2][Test Example 2]

[결정형 확인시험(X-선 스펙트럼 시험)]Crystalline Identification Test (X-Ray Spectrum Test)

실시예 1에서 제조한 결정형세푸록심 악세틸의 X선 스펙트럼을 측정한 결과, 제2도에서 확인할 수 있는 바와 같이 결정형 세푸록심 악세틸의 특징적인 회절스펙트럼을 보여줌으로써 결정형 세푸록심 악세틸이 효과적으로 제조된 것을 알 수 있다.As a result of measuring the X-ray spectrum of the crystalline Sepuroxime Axetyl prepared in Example 1, as shown in FIG. 2, it shows the characteristic diffraction spectrum of the crystalline Sepuroxime Axetyl effectively It can be seen that it was manufactured.

Claims (4)

나트륨 세푸록심(sodium cefuroxime)과 브롬화 (RS)-1-아세톡시에틸을 반응시켜 제조한 세푸록심 악세틸에 물과 에틸아세테이트(ethyl acetate)혼합용액을 가하거나 물을 먼저 가하고 에틸아세태이트를 가하여 교반한 다음, 물로 세척하여 결정형 세푸록심 악세틸을 분리건조하는 것을 특징으로 하는 결정형 세푸록심 악세틸(crystalline cefuoxime sxetile)의 제조방법.A mixture of water and ethyl acetate is added to the cefuroxime acetyl prepared by reacting sodium cefuroxime with brominated (RS) -1-acetoxyethyl, or water is added first, followed by ethylacetate. Method of producing crystalline cefuoxime sxetile characterized in that the mixture is stirred, and then washed with water to separate and dry crystalline cefuroxime axetyl. 제1항에 있어서, 에틸아세테이트의 물에 대한 부피비가 5 내지 20
Figure kpo00041
인 것을 특징으로 하는 결정형 세푸록심 악세틸의 제조방법.
The method of claim 1, wherein the volume ratio of ethyl acetate to water is 5 to 20
Figure kpo00041
A process for producing crystalline cefuroxime axetyl, characterized in that.
제1항에 있어서, 반응온도를 5 내지 35
Figure kpo00042
로 유지시켜 반응시키는 것을 특징으로 하는 결정형세푸록심 악세틸의 제조방법.
According to claim 1, wherein the reaction temperature is 5 to 35
Figure kpo00042
A method for producing crystalline cefuroxime axetyl, characterized in that the reaction is maintained by.
제1항 내지 제3항중 어느 한 항에 있어서, 세푸록심 악세틸이 약 1: 1의 R : S의 이성체비로 결정화되는 것을 특징으로 하는 결정형 세푸록심 악세틸의 제조방법.4. The process according to claim 1, wherein the cefuroxime axetyl is crystallized at an isomer ratio of R: S of about 1: 1. 5.
KR1019970037143A 1997-08-02 1997-08-02 The synthetic method of crystalline cefuroxime axetil KR100228264B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019970037143A KR100228264B1 (en) 1997-08-02 1997-08-02 The synthetic method of crystalline cefuroxime axetil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970037143A KR100228264B1 (en) 1997-08-02 1997-08-02 The synthetic method of crystalline cefuroxime axetil

Publications (2)

Publication Number Publication Date
KR19990015200A KR19990015200A (en) 1999-03-05
KR100228264B1 true KR100228264B1 (en) 1999-11-01

Family

ID=19516816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970037143A KR100228264B1 (en) 1997-08-02 1997-08-02 The synthetic method of crystalline cefuroxime axetil

Country Status (1)

Country Link
KR (1) KR100228264B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020016052A (en) * 2000-08-24 2002-03-04 최현식 New method for the manufacture of amorphous cefuroxime axetil

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100675357B1 (en) 2005-07-23 2007-01-30 삼성전자주식회사 Roller assembly for image forming apparatus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910008377B1 (en) * 1983-07-29 1991-10-12 글락소 그룹 리미티드 Process for preparation of celphaslosporin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910008377B1 (en) * 1983-07-29 1991-10-12 글락소 그룹 리미티드 Process for preparation of celphaslosporin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020016052A (en) * 2000-08-24 2002-03-04 최현식 New method for the manufacture of amorphous cefuroxime axetil

Also Published As

Publication number Publication date
KR19990015200A (en) 1999-03-05

Similar Documents

Publication Publication Date Title
NO165241B (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL ACCEPTABLE SALT OF CLAVULANIC ACID.
KR20180094916A (en) An improved process for the preparation of sugammadex and its intermediates
JPS5935381B2 (en) Method for resolving (+)- and (-)-6-methoxy-α-methyl-2-naphthaleneacetic acid
LU86461A1 (en) PROCESS FOR THE DEPROTECTION OF ALLYL ESTERS AND ETHERS
JPS61197586A (en) 7-amino-o-2-isocephem-4-carboxylic acid compound and manufacture
JP2005516011A (en) Crystalline dihydrate cefnidir potassium
KR100228264B1 (en) The synthetic method of crystalline cefuroxime axetil
JPH0419229B2 (en)
JP3974035B2 (en) 5-Trityloxymethyl-oxazolidinones and process for producing the same
CA1148535A (en) Process for the production of penicillins
KR100214709B1 (en) The synthetic method of amorphous cefuroxime axetil
FR2482104A1 (en) PROCESS FOR THE PREPARATION OF SODIUM CEFUROXIME AND SOLVATE OF SODIUM CEFUROXIME AND TETRAHYDROFURAN OBTAINED BY THIS PROCESS
JPS6391352A (en) Production of optically active phenylpropanolamines
JPH09309896A (en) Glycosidation of colchicine derivative and its formed product
JP2005502651A (en) Method for producing high purity cefuroxime axetil
US4960832A (en) Polymer-supported alkyl azodicarboxylates and their use in Mitsunobu reactions
US3910958A (en) Process for preparing arylacetic acids and esters thereof
CH382729A (en) Process for preparing tetracyclines
CH628906A5 (en) Semi-synthetic derivatives of 4''-erythromycin A and medicinal products containing them
US3947414A (en) Cefamandole derivatives
JP2998154B2 (en) L-Tartrate of (2R.4R) -4-methyl-2-piperidinecarboxylic acid ethyl ester and L-tartrate of (2R.4R) -4-methyl-2-piperidinecarboxylic acid ethyl ester and desalted product thereof Manufacturing method
JPS593476B2 (en) Optically active chlorpheniramine/acylphenylglycine salt and method for producing the same
JP4373080B2 (en) Purification of milbemycins
WO2007036951A2 (en) Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
KR100327708B1 (en) Method for producing crystalline cefuroxime axetil

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040127

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee